Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 8INDUSTRY 4NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 17Gastrointestinal 3Genitourinary 2CNS 2Plasma cell 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Brain Neoplasms 206Glioblastoma 169Central Nervous System Neoplasms 138Astrocytoma 135Gliosarcoma 132Neuroblastoma 109Glioma 104Oligodendroglioma 87Medulloblastoma 68Sarcoma 51Neoplasms 45Ependymoma 43Osteosarcoma 40Wilms Tumor 39Familial ependymoma 38Neuroectodermal Tumors, Primitive, Peripheral 36Optic Nerve Glioma 33Breast Neoplasms 33Lymphoma, Non-Hodgkin 32Neurofibromatosis 1 31Choroid Plexus Neoplasms 29Lymphoma 28Burkitt Lymphoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Rhabdomyosarcoma 23Rhabdoid Tumor 23Recurrence 21Meningioma 21Carcinoma, Non-Small-Cell Lung 21Testicular Neoplasms 20

Interventions

ixabepilone 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Sarcoma, Synovial × CNS × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

NCT00331643 2014-11-14

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡